Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Sep;76(9):1217-21.
doi: 10.1136/jnnp.2004.057893.

Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation

R Hilker  1 , A T Portman, J Voges, M J Staal, L Burghaus, T van Laar, A Koulousakis, R P Maguire, J Pruim, B M de Jong, K Herholz, V Sturm, W-D Heiss, K L Leenders
Affiliations
Clinical Trial

Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation

R Hilker et al. J Neurol Neurosurg Psychiatry. 2005 Sep.

Abstract

Objectives: Glutamate mediated excitotoxicity of the hyperactive subthalamic nucleus (STN) has been reported to contribute to nigral degeneration in Parkinson's disease (PD). Deep brain stimulation of the STN (STN DBS), in its role as a highly effective treatment of severe PD motor complications, has been thought to inhibit STN hyperactivity and therefore decrease progression of PD.

Methods: In a prospective two centre study, disease progression was determined by means of serial (18)F-fluorodopa (F-dopa) positron emission tomography (PET) in 30 patients with successful STN DBS over the first 16 (SD 6) months after surgery.

Results: Depending on the method of PET data analysis used in the two centres, annual progression rates relative to baseline were 9.5-12.4% in the caudate and 10.7-12.9% in the putamen.

Conclusions: This functional imaging study is the first to demonstrate a continuous decline of dopaminergic function in patients with advanced PD under clinically effective bilateral STN stimulation. The rates of progression in patients with STN DBS were within the range of previously reported data from longitudinal imaging studies in PD. Therefore this study could not confirm the neuroprotective properties of DBS in the STN target.

PubMed Disclaimer

Comment in

References

    1. J Neural Transm Suppl. 2000;(60):125-37 - PubMed
    1. Adv Neurol. 2001;86:405-12 - PubMed
    1. Neurology. 2001 Dec 11;57(11):2089-94 - PubMed
    1. J Neurosurg. 2002 Feb;96(2):269-79 - PubMed
    1. Mov Disord. 2002;17 Suppl 3:S69-72 - PubMed

Publication types

Substances